Compare Utilities Select Sector SPDR Fund (XLU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Utilities Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Utilities Select Sector SPDR Fund trades at $41.41 (market cap $23.60B), while Zoetis Inc trades at $74.43 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Utilities Select Sector SPDR Fund for 80 Days and Zoetis Inc for 70 Days on average.
| XLU | ZTS | |
|---|---|---|
Market Cap | $23.60B | $30.20B |
Volume | 28,758,237 | 6,175,327 |
52-Week High | $47.73 | $147.53 |
52-Week Low | $39.25 | $69.09 |
Typical Hold Time | 80 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLU trades at $41.35, up 0.49% with a mixed technical signal showing bullish moving averages but neutral oscillators. The ETF recently hit 52-week lows amid utility sector pressure from rising interest rates. Support levels cluster around $40-41 with resistance at $42. Recent news highlights oversold conditions and defensive positioning opportunities.
The outlook remains cautious with interest rate sensitivity being the primary risk. Defensive characteristics may appeal during market volatility, but sector headwinds from AI power demand shifts and regulatory challenges require monitoring. Current technical positioning suggests near-term consolidation around current levels.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
